Carvykti delays myeloma symptom worsening, per Phase 3 trial data
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
News
Changes in blood cell gene profile may impact leukemia outcomes
In people with acute myeloid leukemia (AML), changes in the gene profile of blood-forming stem cells, leading to a more youthful blood cell profile, could…
PRKAA1 protein seen among pancreatic cancer biomarkers: Study
A protein called PRKAA1 could be among potential pancreatic cancer biomarkers and a possible treatment target, a study found. Levels of the protein were…
Study IDs ways IDH-related brain tumors become more aggressive
Researchers have uncovered genetic changes that may explain why certain brain tumors, known as gliomas, that are associated with IDHÂ gene mutations start off as…
Vulvar cancer possibly tied to bacteria not known in such cancers
The first recorded case of vulvar cancer that occurred alongside an infection with the Fusobacterium necrophorum bacteria was described in a recent case report…
New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
Somatostatin may be safe option for certain tumors during pregnancy
For about one-third of women with a neuroendocrine tumor — or an abnormal mass of tissue that forms from hormone-releasing cells, such as those in…
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell disease models. “These data strongly…
FDA to review combinations of Blenrep for multiple myeloma
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment